Antigenics (AGEN) got Russian approval for its cancer immunotherapy -
a cancer "vaccine" is the sexy, headline grabbing term. This also
created a few seconds of buzz around two other immunotherapy companies,
Dendreon (DNDN) and Cell Genesys (CEGE). I mention these two other
companies because, for purposes of full disclosure, I own CEGE stock
and recommend it in my newsletter service. I also own a full hedged
position of DNDN I cannot wait to liquidate when my hedge expires.
In
the U.S., AGEN has been failing to get approvals from the FDA for good
reasons - their treatment, Oncophage, did not work in Phase III trials
- it did not even come close, which is at least a sort of argument DNDN
could and did make. Oncophage targets kidney cancer and was shown to
work within a sub group of patients with "lower-stage tumors" and
therefore a better shot at survival - and 45% of these patients
responded to Oncophage. Hence, the approval in a Russia looking to
build new industries. Complete Story »
...
Anytime
